New study tracks sorafenib safety in Hard-to-Treat thyroid cancer
NCT ID NCT02185560
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This study monitors 453 patients with advanced thyroid cancer that cannot be removed by surgery and does not respond to radioactive iodine. All patients are taking the drug sorafenib (Nexavar) as part of their normal care. Researchers are tracking side effects and how long patients live or stay on treatment over 9 to 24 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- sorafenib (Nexavar)
- What this could lead to
- If successful, this study will confirm the safety and real-world effectiveness of sorafenib for advanced thyroid cancer, supporting its continued use.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by short follow-up and lack of a comparison group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
453 people
The number who actually took part.
- Started
-
Jun 2014
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients treated with Sorafenib for Unresectable Differentiated Thyroid Carcinoma (DTC)
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who start NEXAVAR treatment for radioactive iodine-refractory unresectable Differentiated Thyroid Carcinoma (DTC) Exclusion Criteria: * Patients who have already received NEXAVAR treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thyroid carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Multiple Locations, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Electric pulses, no needles: a new path to pain relief after thyroid surgery?
- Drug duo aims to starve thyroid tumors
- Could drug holidays improve thyroid cancer treatment?
- New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
- New ultrasound method may cut unnecessary thyroid biopsies
- Tiny scope, big difference? study tests Microscope-Assisted thyroid surgery